Q-omics provides the consensus-scored RPSAP39 profile across patient tissues and cancer cell-line models. RPSAP39 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, RPSAP39 is differentially expressed in 5, with the highest sampling consensus in COAD. Additionally, RPSAP39 RNA expression shows 7,524 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight OV, COAD, and TGCT as cancer lineages where RPSAP39 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPSAP39 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPSAP39 survival associations across molecular data types. RPSAP39 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPSAP39 RNA expression–survival associations across cancer types. High RPSAP39 expression shows unfavorable associations in OV and STAD, but favorable associations in THCA, UVM, SKCM and READ. The OV Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .014). Together, the overview and detailed table identify OV as the clearest survival context for RPSAP39 RNA expression.
This table summarizes RPSAP39 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for RPSAP39. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPSAP39 shows lower tumor expression in BLCA and higher tumor expression in COAD, LUAD, LIHC and UCEC. The COAD box plot shows higher RPSAP39 RNA expression in tumor versus normal tissue (log2 FC = +0.191, t-test p = .004).
This table shows molecular features associated with RPSAP39 in patient tissues and cancer cell lines. In patient samples, RPSAP39 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
